Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Nea Ionia – page 78

1 034 clinical trials in Nea Ionia, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Nea Ionia at a glance
1 034
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 034 trials in Nea Ionia

Open in trial search

COVID-19

Not recruiting

Study on Abatacept for Improving Recovery in Hospitalized COVID-19 Patients

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:University Of Minnesota

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Deep vein thrombosis+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3018250
  • Sponsor:Bayer AG

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Infants

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study of Romiplostim Treatment for Chemotherapy-induced Low Blood Platelets in Adults with Gastrointestinal, Pancreatic, or Colorectal Cancer Receiving Oxaliplatin Chemotherapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Other cities in Greece

The busiest research cities in the country

All 47 cities in Greece

Clinical research in Nea Ionia

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluate new therapeutic approaches for reducing cardiovascular risks.

  • Cardiovascular event prevention
  • Lipoprotein management
  • Heart disease treatments

Advanced trials exploring novel compounds for improved patient outcomes.

02 Atrial Fibrillation Treatment

Comprehensive studies examining various approaches to manage atrial fibrillation, including new medications for stroke prevention and cardiac rhythm control.

  • Stroke prevention therapies
  • Cardioversion treatments
  • Anticoagulation management

Multiple therapeutic options being evaluated for different patient populations.

03 Heart Failure Research

Investigation of innovative treatments for chronic heart failure, focusing on patients with reduced ejection fraction and those with kidney complications.

  • Medication effectiveness studies
  • Combined therapy approaches
  • Cardiovascular outcomes

Evaluating new therapeutic combinations to improve patient survival and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.